Robert Stratta to Muromonab-CD3
This is a "connection" page, showing publications Robert Stratta has written about Muromonab-CD3.
Connection Strength
0.053
-
Stratta R, Shaefer M, Bradshaw K, Wood R, Langnas A, Zetterman R, Donovan J, Sorrell M, Markin R, Shaw BW. Experience with OKT3 after orthotopic liver transplantation. Transplant Proc. 1991 Jun; 23(3):1970.
Score: 0.025
-
Trofe J, Stratta RJ, Egidi MF, Lo A, Gaber LW, Shokouh-Amiri MH, Grewal HP, Honaker M, Hardinger K, Alloway RR, Gaber AO. Thymoglobulin for induction or rejection therapy in pancreas allograft recipients: a single centre experience. Clin Transplant. 2002; 16 Suppl 7:34-44.
Score: 0.013
-
Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J, et al. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group. Transplant Proc. 1993 Feb; 25(1 Pt 1):635-7.
Score: 0.007
-
Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J, et al. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. Transplant Proc. 1993 Feb; 25(1 Pt 1):679-88.
Score: 0.007